- Restart Life Sciences (CSE:HEAL) more than doubled revenue at stable profit margins in Q2 2026 amid several promising commercial activations.
- The Canadian-based company is building a platform of science-backed wellness brands focused on cognitive health, nutrition and functional foods.
- Restart Life Sciences stock last traded at C$0.075 and has given back 16.67 per cent year-over-year.
Restart Life Sciences (CSE:HEAL) more than doubled revenue at stable profit margins in Q2 2026 amid several promising commercial activations, marking a promising start to its transition from a non-revenue issuer to a revenue-producing consumer packaged goods company, following the acquisition of Holy Crap Foods in February.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Revenue came in at C$331,162, up by 146 per cent quarter-over-quarter, with the six-month figure rising to C$465,715, up from nil year-over-year (YoY).
Holy Crap’s functional cereals generated C$110,000 in revenue in June 2026 at a 35 per cent gross margin, representing a 64.2 per cent YoY increase for the brand, leveraging strength across its wholesale, distribution and e-commerce channels.
Gross profit was C$130,699, yielding a 39.5 per cent gross margin, with the six-month figures rising to C$192,636 and 41.4 per cent, respectively.
The company ended the quarter with total assets of C$1,903,647, up from C$1,767,208 as of December 31, 2025.
Looking ahead, leadership is keen to foster market share by leveraging recent online placements with Walmart Canada and Amazon in the United States, an ongoing Caribbean pilot program, as well as a new protein-focused product line in collaboration with the University of Manitoba’s Richardson Centre for Food Technology and Research.
Check out Thursday’s news release for the full story.
Leadership commentary
“Our management team remains focused on strategic growth, revenue generation and market expansion,” Steve Loutskou, Chief Executive Officer of Restart Life Sciences, said in a statement. “Transitioning from a non-revenue issuer a year ago to reporting C$465,715 in revenue for the first half of 2026 reflects the initial integration of our operations. With our presence on digital platforms, our entry into the US market via Amazon and our evaluation of potential M&A opportunities, we continue to execute our business plan, though we recognize the ongoing costs, capital requirements and operational risks necessary to scale the business over the long term.”
About Restart Life Sciences
Restart Life Sciences is a Canadian-based life sciences company building a platform of science-backed wellness brands focused on cognitive health, nutrition and functional foods.
Restart Life Sciences stock (CSE:HEAL) last traded at C$0.075 and has given back 16.67 per cent year-over-year.
Join the discussion: Find out what investors are saying about Holy Crap Foods on the Restart Life Sciences Corp. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
